Acalabrutinib in Frontline CLL Treatment: Six-Year Results from the Elevate-TN Study
In this MEDtalk Dr. Jeff Sharman from Hematology Research for U.S. Oncology presents the six-year follow-up data from the Elevate-TN study. The study explores the comparative effectiveness and safety profiles of acalabrutinib with or without obinutuzumab against standard chemo-immunotherapy in the frontline treatment of Chronic Lymphocytic Leukemia (CLL), including the impact of adding obinutuzumab on progression-free survival and its implications for specific molecular subgroups.
Få tillgång
Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.
- Få tillgång
- Om du redan har en profil: Logga in